Presentations

Date	Title
Feb 13, 2025	Tandem 2025: Narsoplimab Treatment for TA-TMA - Real World Outcomes from an Expanded Access Program 2.1 MB
Feb 13, 2025	Tandem 2025: Narsoplimab for Refractory TA-TMA in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation 694.2 KB
Dec 10, 2024	ASH 2024: Population PK/PD and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH 1.1 MB
Dec 10, 2024	Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway MASP-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study 658.3 KB
Jun 15, 2024	EHA 2024: OMS906 Improved Hematologic Parameters in Patients with PNH and Suboptimal Response to Ravulizumab Treatment - Phase 2 Dose-Finding Study Interim Results 419.2 KB
Jun 06, 2024	2024 Annual Meeting of Shareholders: Corporate Presentation 2.1 MB

You are now leaving Omeros.com